Features of the course of bronchial asthma in patients who have suffered a new coronavirus infection

Objective: to evaluate the clinical status of patients with bronchial asthma in the post-Covid period depending on the severity of the acute period of COVID-19. Materials and methods: a case-control study was conducted of patients diagnosed with asthma who had suffered a coronavirus infection, who turned to the Nizhny Novgorod Regional Pulmonology Center for consultation about asthma. The analysis included 56 patients. The survey methods included two stages: retrospective and prospective. The following scales were assessed: the severity of asthma, the level of asthma therapy, asthma control according to the Global Initiative for Asthma (GINA), and the severity of shortness of breath (mMRC test). Results: the analysis revealed statistically significant differences on all scales, regardless of the severity of the acute course of COVID-19, p <0.005. In the process of data analysis, depending on the severity of the acute period of infection, statistically significant differences in the clinical status before and after COVID-19 were found in patients with mild and moderate coronavirus infection. In patients who had mild COVID-19, clinical status indicators worsened on all scales: asthma severity before COVID-19 ─ 2.00 [2.00–2.00], after COVID-19 ─ 2.00 [2.00–3.00], р<0.005; control according to GINA before COVID-19 ─ 2.00 [2.00–2.00] after COVID-19 ─ 3.00 [2.00–3.00]; step therapy before COVID-19 ─ 3.00 [2.25–3.00], after ─ 4.00 [4.00–5.00], р<0.005; severity of shortness of breath before COVID-19 ─ 1.00 [0.25–1.00], after COVID-19 ─ 2.00 [1.00–2.00], р<0.005. Patients who had moderate COVID-19 also worsened all indicators of clinical status on all scales: severity of asthma before COVID-19 ─ 2.00 [2.00–2.00], after COVID-19 ─ 2.00 [2,00–3.00], p<0.005; control according to GINA before COVID-19 ─ 2.00 [2.00–2.00], after COVID-19 ─ 3.00 [2.00–3.00]; level of therapy before COVID-19 ─ 3.00 [3.00–3.00], after COVID-19 ─ 4.00 [4.00–5.00], p<0.005; severity of shortness of breath before COVID-19 ─ 1,00 [1.00–1.00], after COVID-19 ─ 2.00 [1.00–2.00], p<0.005. Conclusion. еhe results of our study demonstrate the negative impact of SARS-CoV-2 on the clinical status of patients with asthma who have suffered a new coronavirus infection.

1. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730-1741. DOI: 10.1111/all.14238

2. Lombardi C, Gani F, Berti A, Comberiati P, Peroni D, Cottini M. Asthma and COVID-19: a dangerous liaison? Asthma Res Pract. 2021;7(1):9. DOI: 10.1186/s40733-021-00075-z

3. Assaf S, Stenberg H, Jesenak M, Tarasevych SP, Hanania NA, Diamant Z. Asthma in the era of COVID-19. Respir Med. 2023;218:107373. DOI: 10.1016/j.rmed.2023.107373

4. Philip KEJ, Buttery S, Williams P, Vijayakumar B, Tonkin J, Cumella A, et al. Impact of COVID-19 on people with asthma: a mixed methods analysis from a UK wide survey. BMJ Open Respir Res. 2022;9(1):e001056. DOI: 10.1136/bmjresp-2021-001056

5. Agondi RC, Menechino N, Marinho AKBB, Kalil J, Giavina-Bianchi P. Worsening of asthma control after COVID-19. Front Med (Lausanne). 2022;9:882665. DOI: 10.3389/fmed.2022.882665

6. Chiner-Vives E, Cordovilla-Pérez R, de la Rosa-Carrillo D, García-Clemente M, Izquierdo-Alonso JL, Otero-Candelera R, et al. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Arch Bronconeumol. 2022;58 Suppl 1:39-50. DOI: 10.1016/j.arbres.2022.03.011

7. Овсянников Е.С., Авдеев С.Н., Будневский А.В., Дробышева Е.С., Савушкина И.А. Бронхиальная астма и COVID-19: вопросы коморбидности. Туберкулез и болезни легких. 2021;99(9):6-14. DOI: 10.21292/2075-1230-2021-99-9-6-14

8. Muntean IA, Leru PM, Pintea I, Bocsan IC, Dobrican CT, Deleanu D. A retrospective study regarding the influence of COVID-19 disease on asthma. BMC Pulm Med. 2023;23(1):22. DOI: 10.1186/s12890-023-02309-7

9. Kwok WC, Tam TCC, Lam DCL, Leung JKC, Chan KPF, Chan SKS, et al. Worsening of asthma control after recovery from mild to moderate COVID-19 in patients from Hong Kong. Respir Res. 2023;24(1):53. DOI: 10.1186/s12931-023-02363-z

10. Warner JO, Warner JA, Munblit D. Hypotheses to explain the associations between asthma and the consequences of COVID-19 infection. Clin Exp Allergy. 2022;52(1):7-9. DOI: 10.1111/cea.14021

11. Vijayakumar B, Boustani K, Ogger PP, Papadaki A, Tonkin J, Orton CM, et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity. 2022;55(3):542-556.e5. DOI: 10.1016/j.immuni.2022.01.017

12. Lepretre F, Gras D, Chanez P, Duez C. Natural killer cells in the lung: potential role in asthma and virus-induced exacerbation? Eur Respir Rev. 2023;32(169):230036. DOI: 10.1183/16000617.0036-2023